European Drug Regulator Approves AstraZeneca's Two Flagship Cancer Drugs For Breast And Lung Cancer Settings
The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...
AstraZeneca’s Imfinzi combination with chemo approved in EU to treat NSCLC
Imfinzi in combination with chemotherapy has been approved in the European Union, EU, for the treatment of adults with ...
Pharmaceutical Technology on MSN3d
FDA approves AstraZeneca’s Imfinzi combo for bladder cancer
The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody Imfinzi (durvalumab) with ...
Fierce Pharma4d
AstraZeneca bulks up Imfinzi's prowess with FDA nod in bladder cancer around surgery
AstraZeneca has secured another expansion of its Imfinzi for use in cancer patients before and after surgery. | Imfinzi is ...
Zacks Investment Research on MSN3d
AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication
AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer ...
PipelineReview.com9h
Imfinzi-based perioperative regimen approved in the EU for resectable non-small cell lung cancer
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone ...
AstraZeneca (LSE:AZN) Secures EU Approvals; $125 Million Payment Due to Daiichi Sankyo
AstraZeneca (LSE:AZN) has seen a shift recently with the EU approval of ENHERTU® and Imfinzi®, which are likely influential ...
FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients
The U.S. Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc's (NASDAQ:AZN) Imfinzi (durvalumab) in ...
PMLive3d
AstraZeneca’s Imfinzi regimen approved by FDA to treat muscle-invasive bladder cancer
AstraZeneca (AZ) has announced that its Imfinzi (durvalumab) perioperative regimen has been approved by the US Food and Drug ...
The Pharma Letter9h
Two new EU approvals for AstraZeneca
UK pharma major AstraZeneca (LSE: AZN) today reported extended approvals in Europe for two of its cancer drugs: Imfinzi ...
AstraZeneca’s Imfinzi approved in US for treatment of adults with MIBC
Imfinzi in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy ...
AstraZeneca gets EU approval for cancer treatments Enhertu and Imfinzi
The Cambridge, England-based pharmaceuticals firm said Enhertu, or trastuzumab deruxtecan, has been approved in the EU as a therapy for adult patients with unresectable or metastatic hormone ...